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Abstract
The therapeutic potential of ginseng has been studied extensively, and ginsenosides, the active components of 
ginseng, are shown to be involved in modulating multiple physiological activities. This article will review the structure, 
systemic transformation and bioavailability of ginsenosides before illustration on how these molecules exert their 
functions via interactions with steroidal receptors. The multiple biological actions make ginsenosides as important 
resources for developing new modalities. Yet, low bioavailability of ginsenoside is one of the major hurdles needs to be 
overcome to advance its use in clinical settings.
Review
Background
Panax ginseng (Renshen, Chinese ginseng) is commonly
used either by itself or in combination with other medici-
nal ingredients as a key herb in Chinese medicine. A
member of the Araliaceae family, the genus name Panax
was derived from the Greek word meaning "all-healing"
first coined by the Russian botanist Carl A. Meyer. The
Panax family consists of at least nine species, including P.
ginseng,  Panax quinquefolium (Xiyangshen, American
ginseng), Panax notoginseng (Sanqi) and Panax japonicus
(Japanese ginseng). The worldwide sale of ginseng prod-
ucts has estimated to reach US$ 300 million in 2001 [1,2].
Ginseng modulates blood pressure, metabolism and
immune functions [3-6]. The action mechanism of gin-
seng had not been known until ginsenosides were iso-
lated in 1963 [7,8]. Much effort has since been focused on
evaluating the function and elucidating the molecular
mechanism of each ginsenoside. Number of publications
on ginseng and ginsenosides has been growing exponen-
tially since 1975 according to the Pubmed entry.
Ginsenosides are the pharmacologically active 
components in ginseng
Ginsenosides are triterpene saponins. Most ginsenosides
are composed of a dammarane skeleton (17 carbons in a
four-ring structure) with various sugar moieties (e.g. glu-
cose, rhamnose, xylose and arabinose) attached to the C-
3 and C-20 positions [9,10]. Ginsenosides are named as
'Rx', where the 'R' stands for the root and the 'x' describes
the chromatographic polarity in an alphabetical order [7],
for example, Ra is the least polar compound and Rb is
more polar than Ra. Over 30 ginsenosides have been
identified and classified into two categories: (1) the 20(S)-
protopanaxadiol (PPD) (Rb1, Rb2, Rb3, Rc, Rd, Rg3, Rh2,
Rs1) and (2) the 20(S)-protopanaxatriol (PPT) (Re, Rf,
Rg1, Rg2, Rh1). The difference between PPTs and PPDs is
the presence of carboxyl group at the C-6 position in
PPDs [9,10]. Moreover, several rare ginsenosides, such as
the ocotillol saponin F11 (24-R-pseudoginsenoside) [11]
and the pentacyclic oleanane saponin Ro (3,28-O-bisdes-
moside) [12] have also been identified.
The quality and composition of ginsenosides in the gin-
seng plants are influenced by a range of factors bhsuch as
the species, age, part of the plant, cultivation method,
harvesting season and preservation method [13,14]. For
example, ginsenoside Rf is unique to Asian ginseng while
F11 is found exclusively in American ginseng. Thus the
Rf/F11 ratio is used as a phytochemical marker to distin-
guish American ginseng from Asian ginseng [15,16]. The
overall saponin content in ginseng is directly propor-
tional to its age, reaching a peak level at around 6 years of
age [17,18]. Most harvested ginseng roots are air-dried
while some are steamed at 100°C for two to four hours
before drying, which gives the ginseng a darker appear-
ance known as red ginseng. The red ginseng has a unique
saponin profile, with emerging ginsenosides Ra1, Ra2,
Ra3, Rf2, Rg4, Rg5, Rg6, Rk1, Rs1 and Rs2 being likely the
results of heat transformation and deglycosylation of nat-
urally occurring ginsenosides [19-24]. The presence of
these compounds may confirm the folk knowledge that
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red ginseng is of higher medicinal values than the white
one [25].
Sun ginseng is a new type of processed ginseng that is
steamed at 120°C. The new process aimed to increase the
levels of anti-tumor ginsenosides Rg3, Rg5 and Rk1 [26-
30]. Moreover, the butanol-soluble fraction of Sun gin-
seng is formulated into KG-135 which contains Rk3 Rs3,
Rs4, Rs5, Rs6 and Rs7 in addition to the major anti-tumor
ginsenosides [31].
Standardized ginseng extracts
To avoid variability among preparations, many research-
ers use commercially available standardized ginseng
extracts. Two commonly used standardized extracts are
G115 from P. ginseng (total ginsenoside adjusted to 4%)
(Pharmaton SA, Switzerland) and NAGE from P. quin-
quefolius  (total ginsenoside content adjusted to 10%)
(Canadian Phytopharmaceuticals Corporation, Canada).
Studies on these two ginseng extracts using high-perfor-
mance liquid chromatography (HPLC) found ginseno-
sides Rb1, Rb2, Rc, Rd, Re and Rg1 in both G115 and
NAGE, and ginsenoside Rg2 in G115 only. To compare
between G115 and NAGE, G115 has higher Rg1, but
NAGE has higher in Rb1 and Re [32-34].
Ginsenosides are part of the defense mechanisms in 
ginseng
Similar to plants that produce insect repellents and anti-
m i c r o b i a l  s u b s t a n c e s  a s  p a r t  o f  t h e i r  d e f e n s e  m e c h a -
nisms, e.g. nicotine from tobacco leaves [35], rotenone
from derris tree roots [36], pyrethroids from chrysanthe-
mum flowers [37], and triterpenoids from neem tress
[38], evidence suggests that ginsenosides may protect
ginseng. Addition of methyl jasmonate (a plant-specific
signaling molecule expressed during insect and patho-
genic attacks) into ginseng in vitro cultures enhances gin-
senoside production [39-41]. Naturally occurring
ginsenosides are antimicrobial and antifungal; the bitter
taste of ginsenosides makes them antifeedant [42-46].
Furthermore, ginsenosides may act as ecdysteroids, the
insect molting and metamorphosis hormones, due to the
structural similarities between the two groups of chemi-
cals. The ecdysteroids have a steroid backbone with a C-
20 sugar side-chain and a C-3 hydroxyl group [47] resem-
bling the structure of most of the PPT-type ginsenosides
such as Rg1 and several metabolites of PPDs such as com-
pound Y and compound K. Ecdysteroids differ from gin-
senosides in the C-6 position which is occupied by an
oxygen group is in the former and a hydrogen or hydroxyl
group in the latter [47]. Such difference, however, has
minor and non-significant influence on ecdysteroid
receptor binding affinity as demonstrated by biochemical
analysis [47,48]. The structural similarity suggests that
certain naturally occurring ginsenosides may disrupt
insects' life cycle by binding to ecdysteroid receptor.
Biotransformation of ginsenosides
Treatment of various cultured cells by ginsenosides
revealed multiple bioactivities, including neuroprotec-
tion [49-53], antioxidation [54-56], angiogenesis modula-
tion [57-59] and cytotoxicity [60-62]. However,
biotransformation may be required before ginsenosides
becoming active in mammalian systems. Recent studies
demonstrated that ginsenoside metabolites had greater
biological effects than ginsenosides [63-65]. Anti-tumor
activities of Rh2 and PD, which are the metabolites of
Rg3, are more potent than those of ginsenoside Rg3 [64].
Ginsenosides Rb1, Rb2, Rg1 and Re do not possess the
same human liver enzyme cytochrome P450 inhibitory
effects of compound K, PT and PD which are the intesti-
nal metabolites of PPTs and PPDs [65].
Major ginsenosides, such as Rg1, Rg3, Rb1, Re and Rc,
are treated as antigens by mammalian systems. Antibod-
ies against these ginsenosides have been purified from
immunized animals [66-70]. Due to their bulky molecular
structures, the ginsenosides are poorly membrane per-
meable and prone to degradation. Oral consumption of
ginseng preparations exposes ginsenosides to acid hydro-
lysis accompanied by side-reactions, glycosyl elimination
and epimerization of C-20 sugar moiety [71,72]. The C-3
or C-20 oligosaccharides are also cleaved by intestinal
microflora stepwise from the terminal sugar [72,73].
These intestinal microflora include Prevotella oris [74],
Eubacterium A-44 [75],  Bifidobacterium sp. [73,76],
Bacteroides JY6 [73], Fusbacterium K-60 [73], Lactobacil-
lus delbrueckii sp. [76] and Aspergillus sp. [76]. Following
biodegradation, compound K and protopanaxadiol (PPD)
are the major metabolites of PPDs while PPTs are con-
verted to F1 and protopanaxatriol (PPT) (Figure 1).
Pharmacokinetic and bioavailability of ginsenosides
How intact and transformed ginsenosides are absorbed
and transported to the human system remains elusive.
Transport of ginsenosides across the intestinal mucosa is
energy-dependent and non-saturable [77-79]. The
sodium-dependent glucose co-transporter 1 may be
involved in this process [80]. The availability of intact gin-
senosides and their metabolites from the intestines is
extremely low [81-83]. For example, only 3.29% Rg1 and
0.64% Rb1 are detected in rat serum after oral adminis-
tration of ginsenosides [78,79], confirming the classic
studies by Odani et al. in 1983 [84,85]. Rg1 levels become
undetectable within 24 hours of oral consumption while
Rb1 levels remain relatively stable for three days [83].
Experiments to increase the bioavailability of ginseno-
sides include co-administration of ginsenosides with
adrenaline [86], emulsification of ginsenosides into lipid-Leung and Wong Chinese Medicine 2010, 5:20
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Figure 1 Biodegradation of ginsenosides by intestinal microflora. PPDs and PPTs are deglycosylated to end-metabolites protopanaxadiol (PPD) 
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based formulation [87,88] and suppression of p-glycopro-
tein efflux system [77]. P-glycoprotein-mediated multi-
drug resistance is a major obstacle to effective cancer
treatments. As ginsenoside Rg3 blocks drug efflux by
inhibiting p-glycoprotein activities and reducing mem-
brane fluidity, it is used to assist cancer chemotherapy
[28,89,90].
Ginsenosides are agonists to steroidal receptors
Ginsenosides modulate expressions and functions of
receptors such as receptor tyrosine kinases (RTK) [91],
serotonin receptors (5-HT) [92], NMDA receptors [93]
and nicotinic acetylcholine receptors (AChR) [94]. Direct
interactions of ginsenosides with the receptor ligand-
binding sites have only been demonstrated in steroid hor-
mone receptors; ginsenosides Rg1 [58,95,96] and Re [97]
are functional ligands of the glucocorticoid receptor (GR)
while ginsenosides Rh1 and Rb1 are functional ligands of
the estrogen receptor (ER), in particular, the ER beta iso-
form of Rb1 [59,98]. These findings provide an explana-
tion for the aggravation of menopausal symptoms by
ginsenosides [99,100] and modulation of the endocrine
system in the case of chronic consumption of ginseng
[3,4].
Glucocorticoid is a stress hormone to elicit 'fight-or-
flight' responses through GR activation. If Rg1 and Re are
functional ligands of GR, how is ginseng adaptogenic and
antistress? Rg1 and Re may behave as partial agonists to
GR. Both Rg1 and Re inhibit the binding of the synthetic
glucocorticoid dexamethasone to GR and 100% displace-
ment is possible when ginsenosides are in excess [96,97].
Since Rg1 and Re elicit biological activities that are GR
inhibitor RU486 sensitive, indicating these ginsenosides
are agonists, but not inhibitors for GR [58,96]. And it is
because the steroidal effects of Rg1 and Re are not as
prominent as dexamethasone, these ginsenosides are
likely to be partial agonist of GR [58,96]. Under physio-
logical conditions, ginsenosides may compensate the
insufficient steroidal activities, when the intrinsic ligand
is absent or inadequate in the system. On the other hand,
ginsenosides can reversibly occupy certain percentage of
the steroidal receptor at low affinity to counter the steroi-
d a l  e f f e c t s  w h e n  t h e y  c o - e x i s t  w i t h  a  l a r g e  a m o u n t  o f
intrinsic ligand.
Moreover, each ginsenoside is able to bind to multiple
steroid hormone receptors. In addition to GR, ginseno-
side Rg1 acts through ER and elicits cross-talking with
insulin-like growth factor-1 receptor (IGF-IR) in neu-
ronal cells [101]. Effects of ginsenoside Re on cardiac
myocytes are related to ER alpha isoform, androgen
receptor and progesterone receptor [102]. The end-
metabolites PD and PT bind and activate both GR and ER
in endothelial cells [103]. The multi-target properties of
ginsenosides may explain why ginseng has a wide range of
beneficial effects.
Conclusion
As partial agonists to multiple steroidal receptors, ginse-
nosides are important natural resources to be developed
into new modalities, and may replace steroids in the cur-
rent regimen to lessen undesirable side effects. However,
low bioavailablilities of ginsenosides and its metabolites
means that most of these compounds do not reach the
intended biological system when administered orally. The
results of ginsenoside researches will become physiologi-
cal relevant only when (1) the pure compounds of the
ginsenosides is available in large quantities; (2) the ginse-
nosides are biochemically stabilized to avoid degradation
and enhance absorption in the gastrointestinal tract; and/
or (3) special delivery methods for the ginsenosides to
reach the areas of treatment. Moreover, this review high-
lighted the necessary of ginsenoside transformation to
exert its greatest effects in the mammalian system, thus
accelerating this process would help maximizing the
remedial effects of ginsenosides. Addressing these two
issues in the near future would advance ginseng
researches and enhance the possibility for ginseng to be
used clinically.
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